drugset

drugset / Trial / NCT02298920

AZD0914 Phase 1 ADME Study in Healthy Volunteers

NCT02298920 ↗

Phase 1 Completed 6 enrolled Entasis Therapeutics

Non-randomizedSingle-groupOpen-labelBasic science

Summary

This study will investigate the metabolic fate and routes of excretion of 14CAZD0914 in six male healthy volunteers.

Timeline

Start: 2015-01
Primary completion: 2015-02
Completion: 2015-02

Publications

O'Donnell J, Lawrence K, Vishwanathan K, Hosagrahara V, Mueller JP. Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01808-18. doi: 10.1128/AAC.01808-18. Print 2019 Jan.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zoliflodacin	Small molecule	3000 mg	Oral

Indications

No indication recorded.